Search Results
Your search for The ASCO ,The ASCO matches 21374 pages
Showing 6601 - 6650ASCO Issues Comprehensive Recommendations to Strengthen Cancer Care and Research During and Beyond the COVID-19 Pandemic
On December 8, ASCO issued comprehensive recommendations to guide the cancer community’s eventual recovery from the COVID-19 pandemic. By applying lessons learned during the pandemic, ASCO’s Road to Recovery Report: Learning From the COVID-19 Experience to Improve Clinical Research and Cancer Care...
Caron A. Jacobson, MD, on Treating Large B-Cell Lymphoma With Axicabtagene Ciloleucel
Caron A. Jacobson, MD, of the Dana-Farber Cancer Institute, discusses results from the ZUMA-9 C2 study, an ongoing trial that is exploring axicabtagene ciloleucel in patients with relapsed or refractory large B-cell lymphoma (Abstract 2100).
Matthew S. Davids, MD, on CLL/SLL: New Data on Ibrutinib, Venetoclax, and Rituximab Therapies
Matthew S. Davids, MD, of Dana-Farber Cancer Institute, summarizes three key studies from a session he co-moderated on ibrutinib plus venetoclax for first-line treatment of patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), long-term responses to these agents for ...
David T. Teachey, MD, on Pediatric Leukemia and Lymphoma: New Findings on Cranial Radiation and Bortezomib
David T. Teachey, MD, of the University of Pennsylvania and Children’s Hospital of Philadelphia, discusses data showing that cranial radiation might be eliminated in most children with T-cell acute lymphoblastic leukemia and that bortezomib may improve survival in children with T-cell lymphoblastic ...
ASH 2020: Chemotherapy Plus Blinatumomab for Philadelphia Chromosome–Negative B-Cell ALL
Results from a phase II study presented by Nicholas J. Short, MD, and colleagues at the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition (Abstract 464) showed that first-line treatment with a regimen of chemotherapy combined with the monoclonal antibody blinatumomab...
Jyoti Nangalia, MBBChir, on MPN: A New Paradigm for the Development of Blood Cancer?
Jyoti Nangalia, MBBChir, of Wellcome Sanger Institute and the University of Cambridge, discusses how her team used large-scale whole-genome sequencing to precisely time the origins of a blood cancer and measure how it grew. The information could provide opportunities for early diagnosis and...
Sagar Lonial, MD, on CAR T-Cell Therapies for Myeloma: Novel Approaches and Longer-Term Follow-up Data
Sagar Lonial, MD, of the Emory University School of Medicine, summarizes key papers presented in a session he co-moderated on how second-generation CAR T cells can be used to treat patients with multiple myeloma (Session 653).
ASH 2020: Role of Venetoclax in High-Risk Myeloid Malignancies
The BCL2 inhibitor venetoclax can be safely added to standard therapies for some high-risk myeloid blood cancers, and in early studies, the combination showed improved outcomes, according to two reports presented by Jacqueline S. Garcia, MD, and colleagues at the 2020 American Society of Hematology ...
ASH 2020: Subcutaneous Teclistamab for Relapsed or Refractory Multiple Myeloma Studied in Phase I Trial
A subcutaneous injection of the BCMAxCD3 bispecific antibody teclistamab was found to be safe and elicited responses in a majority of patients with relapsed or refractory multiple myeloma, according to findings from a multi-institutional phase I study presented by Alfred L. Garfall, MD, and...
ASH 2020: Environmental Surface Testing for Presence of SARS-CoV-2 in Inpatient and Outpatient Hematology/Oncology Settings
A research team from Rutgers Cancer Institute of New Jersey evaluated the presence of SARS-CoV-2 on various environmental surfaces in outpatient and inpatient hematology/oncology settings. The study revealed extremely low detection of SARS-CoV-2 on environmental surfaces across multiple outpatient...
Curtis Lachowiez, MD, on AML: Venetoclax in Combination With Standard Intensive Induction/Consolidation Therapy
Curtis Lachowiez, MD, of The University of Texas MD Anderson Cancer Center, discusses an interim analysis of a phase Ib/II study showing that venetoclax plus chemotherapy represents an effective regimen, particularly in patients with newly diagnosed and relapsed or refractory acute myeloid...
Mohandas Narla, DSc, Receives 2020 Wallace H. Coulter Award for Lifetime Achievement in Hematology
The American Society of Hematology (ASH) presented Mohandas Narla, DSc, of the New York Blood Center, with the 2020 Wallace H. Coulter Award for Lifetime Achievement in Hematology. Dr. Narla is being recognized for his significant contributions to hematology through his groundbreaking research, his ...
2020 Ernest Beutler Lecture and Prize Presented to Ari Melnick, MD, and Courtney DiNardo, MD
The American Society of Hematology (ASH) will honor Ari Melnick, MD, of Weill Cornell Medicine in New York, and Courtney DiNardo, MD, of the University of Texas MD Anderson Cancer Center, with the 2020 Ernest Beutler Lecture and Prize for their significant research contributions to the treatment...
ASH 2020: Novel Antibody-Drug Conjugate Shows Activity in Rare, Aggressive Form of Leukemia
A phase I/II study found that IMGN632, a novel CD123-targeting antibody-drug conjugate, was tolerable and resulted in a 29% overall response rate in patients with relapsed or refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare but aggressive form of leukemia. Treatment with the...
ASH 2020: Clonal Hematopoiesis in Donors Aged 40 and Older May Be Linked to Improved Survival in Stem Cell Transplant Recipients
A study presented by Christopher Gibson, MD, and colleagues at the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition (Abstract 80) has revealed for the first time that clonal hematopoiesis may confer a health benefit in allogeneic stem cell or bone marrow transplants....
ASH 2020: Early Research Shows CD58 May Be a Biomarker for Response to Axicabtagene Ciloleucel in Patients With Large B-Cell Lymphoma
Although the immunotherapy axicabtagene ciloleucel has significantly improved treatment outcomes for some patients with large B-cell lymphoma, not all patients benefit. In a new study presented by Robbie G. Majzner, MD, and colleagues at the 2020 American Society of Hematology (ASH) Annual Meeting ...
Radhika Gangaraju, MD, and Smita Bhatia, MD, MPH, on Coronary Heart Disease Risk in Blood or Marrow Transplant Survivors
Smita Bhatia, MD, MPH, and Radhika Gangaraju, MD, both of the Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, discuss findings that showed survivors of bone marrow transplants are at a 7- to 12-fold higher risk of coronary heart disease than a sibling comparison ...
Emmanuel Bachy, MD, PhD, on Peripheral T-Cell Lymphoma: Romidepsin Plus CHOP
Emmanuel Bachy, MD, PhD, of the Hospices Civils de Lyon, discusses the final analysis of a phase III study of adding romidepsin to chemotherapy in patients with previously untreated peripheral T-cell lymphoma. Adding romidepsin did not improve progression-free survival and was associated with high...
Corey Cutler, MD, MPH, on MDS: Evaluating Treatments in Older Patients With Advanced Disease
Corey Cutler, MD, MPH, of Dana-Farber Cancer Institute, discusses results from a multicenter trial that compared reduced-intensity allogeneic hematopoietic cell transplantation to hypomethylating therapy or best supportive care in patients aged 50 to 75 with advanced myelodysplastic syndromes...
ASH 2020: SARS-Cov-2 Multivirus-Specific T Cells for the Treatment of Hospitalized Patients With COVID-19
Researchers have successfully built banks of SARS-CoV-2–specific T cells obtained from people who recovered from the virus that are now poised to be used as an experimental treatment in patients hospitalized with COVID-19. This T cell–based therapy may represent a step forward in the search for...
Ann-Kathrin Eisfeld, MD, on AML in Black Patients: Racial Disparities in Survival Outcomes
Ann-Kathrin Eisfeld, MD, of The Ohio State University Comprehensive Cancer Center, discusses SEER data showing that patients with acute myeloid leukemia who are Black and younger than age 60 may have poor survival outcomes, a disparity that should be addressed and further studied to establish...
Options for Maintenance Therapy for Metastatic Pancreatic Cancer
Pancreatic cancer remains one of the most difficult-to-treat cancer types. Although there have been some advances in the past few years, the needle has not moved much on survival and prognosis. An important issue for those patients with metastatic pancreatic cancer who respond to front-line...
ASH 2020: Study Finds Prophylactic Tranexamic Acid Has No Effect on Bleeding in Patients With Hematologic Malignancies
The clot stabilizer tranexamic acid performed no better than placebo when administered prophylactically to prevent bleeding in patients with hematologic malignancies who also received routine prophylactic platelet transfusions, according to findings presented by Terry B. Gernsheimer, MD, and...
Complexity of Designing Clinical Trials for Sarcoma: Shifting Focus to Constellation of Subtypes
Sarcoma has bedeviled researchers for many years because of its heterogeneity. Sarcoma encompasses more than 100 different subtypes, which makes it difficult to design studies to identify effective therapies. As researchers dig deeper into the constellation of subtypes of sarcoma, some therapies...
Study Shows Regional Variation in Genomic Testing for Men With Prostate Cancer
A study published by Michael S. Leapman, MD, and colleagues in JAMA Oncology found substantial regional variation in the use of genomic testing for prostate cancer, raising questions about access and other factors that might promote rapid adoption of new cancer technologies. “Little was known...
FDA Pipeline: Agents in DLBCL, SCLC, AML, and More
Recently, the U.S. Food and Drug Administration (FDA) has issued regulatory decisions for agents to treat diffuse large B-cell lymphoma (DLBCL), small cell lung cancer (SCLC), acute myeloid leukemia (AML), biliary tract cancer, and graft-vs-host disease. Priority Review for Loncastuximab Tesirine...
Subgroup Analysis of Japanese Patients With Ovarian Cancer Treated With Maintenance Olaparib/Bevacizumab
Findings from a subgroup analysis of the phase III PAOLA-1/ENGOT-ov25 study presented by Fujiwara et al at the ESMO Asia Virtual Congress 2020 showed that the addition of olaparib to bevacizumab maintenance following standard platinum-based therapy plus bevacizumab provided a progression-free...
Social Needs May Be Linked to Low Health-Related Quality of Life Among Black Cancer Survivors
Social needs—such as food and economic insecurity, poor housing and neighborhood conditions, and lack of access to transportation—were common in a group of Black cancer survivors in Detroit. These factors were associated with lower health-related quality of life, according to findings published by...
FDA Approves Pralsetinib for RET-Altered Thyroid Cancers
On December 1, the U.S. Food and Drug Administration (FDA) approved pralsetinib (Gavreto) for adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer who require systemic therapy, or for patients with RET fusion–positive thyroid cancer...
FDA Approves Gallium-68 PSMA-11 for PSMA-Targeted PET Imaging in Prostate Cancer
On December 1, the U.S. Food and Drug Administration (FDA) approved gallium-68 PSMA-11—the first drug for positron-emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA)-positive lesions in men with prostate cancer. Gallium-68 PSMA-11 is indicated for patients with suspected ...
Phase II Study of Combination Immunotherapy for Advanced Nasopharyngeal Cancer
Dual CTLA-4/PD-1 blockade with ipilimumab plus nivolumab provided durable responses in patients with recurrent or metastatic nasopharyngeal carcinoma, according to updated efficacy and safety findings from a phase II study presented by Kao et al at ESMO Asia Virtual Congress 2020 (Abstract 266O)....
Does Concurrent Treatment With Dexamethasone Diminish the Efficacy of Immune Checkpoint Inhibitors in Patients With Glioblastoma?
Among patients with glioblastoma receiving an immune checkpoint inhibitor, those who received the corticosteroid dexamethasone at baseline for cerebral edema had significantly worse overall survival, according to results of a study published by Iorgulescu et al in Clinical Cancer Research....
FDA Announces Advisory Committee Meeting to Discuss Second COVID-19 Vaccine Candidate
The U.S. Food and Drug Administration (FDA) has scheduled a meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) for December 17 to discuss the request for emergency use authorization (EUA) for a COVID-19 vaccine from Moderna Inc. “In keeping with the FDA’s commitment ...
ESMO Asia 2020: Performance of Immunoscore in Asian Patients With Early-Stage Colon Cancer
The Immunoscore assay can assess the risk of disease recurrence in Asian patients with early-stage colon cancer and may be used together with TNM classification to guide clinical decision-making, according to findings presented at the European Society for Medical Oncology (ESMO) Asia Virtual...
FDA Grants Accelerated Approval to Naxitamab for High-Risk Neuroblastoma in Bone or Bone Marrow
On November 25, the U.S. Food and Drug Administration (FDA) granted accelerated approval to naxitamab (Danyelza) in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) for pediatric patients aged 1 year and older and adult patients with relapsed or refractory high-risk...
Conquer Cancer®
When you donate to Conquer Cancer®, the ASCO Foundation by December 31, you help patients everywhere maintain access to critical programs and research breakthroughs for all types of cancer. Give today at CONQUER.ORG. © 2020. American Society of Clinical Oncology. All rights reserved.
ASCO’s Free App for Patients: Cancer.Net Mobile
Tell your patients about the award-winning mobile app from Cancer.Net! This intuitive, on-the-go tool helps patients and caregivers plan and manage cancer care—from diagnosis through treatment and beyond. Make sure your patients are getting the latest trusted, oncologist-approved cancer information ...
ASCO Launches Educational Series on Social Determinants of Health
As part of its ongoing commitment to addressing inequities in cancer care and research, ASCO has launched an educational series focused on the role of social determinants of health in cancer care and outcomes. The free series, which kicked off in October, will help educate oncology trainees and...
New Global Survey Finds More Education Needed to Increase Provider Geriatric Assessments for Older Adults With Cancer
Oncology providers familiar with ASCO’s guideline on older adults with cancer are two to four times more likely to conduct a geriatric assessment on patients with cancer over the age of 65, according to the first international ASCO survey aimed at determining if and how often cancer providers are...
Time Is Running Out: Prepare for 2021 E&M Changes Today
Significant changes are coming to the office and outpatient Evaluation and Management (E&M) services Current Procedural Terminology (CPT®) codes (99202-99215). Practices, physicians, and staff who have not done so already must begin preparing for these changes today to ensure a successful...
Gateway for Cancer Research and Conquer Cancer Offer Grant Funding to Research Health Disparities
Gateway for Cancer Research® is investing $1.5 million to ensure that a more diverse patient population is represented in oncology research and to expand clinical trial access for patients from underserved and underrepresented communities. The second biennial Gateway Discovery Grant, administered...
Job Loss During Cancer: How to Cope and Continue Treatment
Job loss is stressful no matter the circumstances. Recently, millions of people have lost their jobs during the COVID-19 pandemic. To make matters more difficult, job loss in the United States can often mean a loss of health insurance. For people with cancer, losing a job is especially challenging...
ELNEC Project Reaches Historic Milestone in End-of-Life Care
The End-of-Life Nursing Education Consortium (ELNEC) project is ending 2020 by surpassing a goal established 20 years ago, reporting more than 1 million nurses and other professionals trained using the ELNEC curriculum. Administered through a partnership between the American Association of Colleges ...
Rogel Team at University of Michigan Receives $11.2M to Leverage the Microbiome Against Graft-vs-Host Disease
A team of researchers from the University of Michigan Rogel Cancer Center in Ann Arbor received an $11.2 million grant from the National Heart, Lung, and Blood Institute to study how to use the microbiome to limit complications of stem cell transplants for blood cancers and other diseases....
U.S. Multisociety Task Force on Colorectal Cancer Offers Management Strategies for Malignant Colorectal Polyps
Early identification and removal of cancerous colorectal polyps are critical to preventing the progression of colorectal cancer and improving survival rates. The U.S. Multisociety Task Force on Colorectal Cancer has released new guidance for endoscopists on how to assess colorectal lesions for...
Global Cancer Institute Extends Programs to Bangladesh for Underserved Patients With Cancer
Global Cancer Institute (GCI), which is focused on improving survival rates for underserved patients with cancer worldwide, recently announced it has extended its programs to Bangladesh. The extension begins with the launch of monthly tumor boards, which help physicians and oncologists in...
Expect Questions About Mohs Micrographic Surgery
A recent study finding similar overall survival rates for patients with melanomas of the trunk and extremities treated with Mohs micrographic surgery or wide local excision1 raises questions about why and when physicians might recommend, and patients opt for, one or the other procedure. “The most...
Mohs Surgery vs Wide Local Excision for Trunk and Extremity Melanomas: Comparable Overall Survival Rates
A cohort study of 188,862 cases of all-stage melanomas of the trunk and extremities found no differences in overall survival between patients treated with Mohs micrographic surgery or with wide local excision.1 “These findings add to the existing body of evidence demonstrating that wide local...
Yes, Men Get Breast Cancer, Too
You could call it a sixth sense, but the moment I felt a lump in my left breast I knew it was cancer, although it would take several weeks to confirm the diagnosis. When I saw my primary cancer physician and told him of my concern, he said: “Don’t worry. Men don’t get breast cancer; it’s a woman’s...
Penn Medicine Researchers Receive $5.4 Million Grant to Find Genetic Drivers of Testicular Cancer
The international hunt to find more genetic risk markers for testicular cancer is expanding. A team of researchers led by Katherine L. Nathanson, MD, Deputy Director of the Abramson Cancer Center and the Pearl Basser Professor for BRCA-Related Research in the Perelman School of Medicine at the...
